9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Estimated reading time: < 1 min

Condition

Carcinoma, Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical Cancer

Estimated Enrollment: 24

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: UCCI-EXP-16-01

Study First Received: January 13, 2017

Last Updated: January 13, 2017

Estimated Primary Completion Date: January 2020

Primary Outcome Measures:

Dose-limiting toxicity of the combination of bosutinib and pemetrexed|Maximum tolerated dose of the combination of bosutinib and pemetrexed|Adverse events of the combination of bosutinib and pemetrexed|Anti-tumor response rate|Progression-free survival

Sponsors and Collaborators:

Nagla Karim|University of Cincinnati

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT03023319

Was this article helpful?
Views: 100